Citations 745

IC‐P‐148: 11C‐PiB PET and hippocampal volumes are complementary in distinguishing dementia with Lewy bodies and Alzheimer's disease

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2009.05.120

O3‐01‐04: Serial FDG and PiB PET in cognitive impairment

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2009.05.424

IC‐P3‐216: Automated ROI analysis of 11C Pittsburgh Compound B images using structural magnetic resonance imaging atlases

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2008.05.161

IC‐P3‐205: Development of novel 18F Aβ amyloid imaging agents

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2008.05.149

IC‐P3‐196: Clinical evaluation of 18F‐labeled AV‐138 for PET amyloid imaging in Alzheimer's disease

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_3 | Pages: No page available

10.1016/j.jalz.2008.05.140

P1‐288: Automated ROI analysis of 11C Pittsburgh compound B images using structural magnetic resonance imaging atlases

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2008.05.878

P1‐161: 11C PiB and structural magnetic resonance imaging in mild cognitive impairment

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2008.05.749

IC‐P1‐031: 11C PiB and structural magnetic resonance imaging in Mild Cognitive Impairment

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2008.05.042

18 F-FDG PET in the Management of Patients with Anaplastic Thyroid Carcinoma

Thyroid® | July 17, 2008 | Volume: 18 | Issue: 7 | Pages: 713-719

10.1089/thy.2007.0350 | PMID 18630999

Background: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors in humans. The use of positron emission tomography (PET) with 18 F-fluorodeoxyglucose ( 18 F-FDG) in ATC has not been studied, and only a few case reports have been published. The objective of this study was to investigate the potential contribution of 18 F-FDG PET to the clinical management of patients with ATC. Methods: All patients with ATC studied with 18 F-FDG PET from August 2001 through March 2007 were included. The PET results were correlated with computed tomography, ultrasound, magnetic resonance imaging, bone scan, histology, and clinical follow-up. The FDG uptake was semiquantified as maximum standard uptake value. Any change in the treatment plan as a direct result of the PET findings as documented in the clinical notes was recorded. Results: Sixteen patients were included. True-positive PET findings were seen for all primary tumors, in all nine patients with lymph node metastases, in five out of eight patients with lung metastases, and in two patients with distant metastases other than lung metastases. In 8 of the 16 patients, the medical records reported a direct impact of the PET findings on the clinical management. Conclusions: ATC demonstrates intense uptake on 18 F-FDG PET images. In 8 of the 16 patients (50%), the medical records reported a direct impact of the PET findings on the management of the patient. PET may improve disease detection and have an impact on the management of patients with ATC relative to other imaging modalities.
O1–04–08: PIB and MRI provide complementary information in imaging of AD and MCI

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.084